Regeneron Pharmaceuticals REGN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's stock-based comp?
- Regeneron Pharmaceuticals (REGN) reported stock-based comp of $257.4M in Q1 2026.
- How has Regeneron Pharmaceuticals's stock-based comp changed year-over-year?
- Regeneron Pharmaceuticals's stock-based comp increased by 0.7% year-over-year, from $255.7M to $257.4M.
- What is the long-term trend for Regeneron Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's stock-based comp has grown at a 13.4% compound annual growth rate (CAGR), from $601.7M to $993.7M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.